Fusion Biopsy Market worth $0.91 billion by 2029
The report "Fusion Biopsy Market by Route Type (Transrectal, Transperineal), Product (Equipment, Consumables), Application (Prostate Cancer), End User (Hospitals), and Region - Global Forecast to 2029", is expected to grow from USD 0.65 billion in 2024 to 0.91 billion by 2029 at a CAGR of 7.1% . The increasing prevalence of prostate cancer and the growing geriatric population, the availability of reimbursements & investments by the public and private sectors, and the increasing prevalence of minimally invasive surgery contribute to the market growth. Furthermore, technological advancements in fusion biopsy devices offer growth opportunities for market players in this market.
Browse 191 market data Tables and 45 Figures spread through 196 Pages and in-depth TOC on "Fusion Biopsy Market by Route Type (Transrectal, Transperineal), Product (Equipment, Consumables), Application (Prostate Cancer), End User (Hospitals), and Region - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/fusion-biopsy-market-228439168.html
In 2023, the transrectal segment held the largest share of the fusion biopsy market, by route type segment.
Based on route type, the global fusion biopsy market is segmented into transrectal, transperineal, and other route types. In 2023, transrectal led the fusion biopsy market. Due to its extensive use in the diagnosis of prostate cancer, the transrectal approach accounts for the biggest portion of the fusion biopsy market. Because of its extensive knowledge among urologists, well-established clinical procedures, ease of access to the prostate, and quicker procedure duration, it is the recommended method for fusion biopsy.
“The prostate cancer segment is projected to witness the highest growth rate in the fusion biopsy market, in 2023, by application”
The market for fusion biopsy is divided into segments based on application, such as prostate cancer and others. Due to the rising incidence of prostate cancer worldwide and the growing need for precise diagnostic methods, the prostate cancer segment of the fusion biopsy market is projected to develop at the fastest rate. As prostate cancer remains a leading concern in men’s health, this segment will continue to drive the adoption of fusion biopsy systems worldwide.
The Europe market the highest share of fusion biopsy market in 2023.
The global fusion biopsy market is segmented into six distinct regions: North America, Europe, Asia Pacific, Middle East & Africa, Latin America, and GCC Countries. The Europe holds the highest share of 33.7% of global fusion biopsy market in 2023. The high share of Europe market can be attributed to the growing geriatric population, extensive healthcare expenditure and supportive government investments support the fusion biopsy market in this region. High demand for diagnosis of prostate cancer along with supportive regulatory environment in Europe for new technologies has also driven the growth of the market.
Prominent players in the market include Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), KOELIS (France), FUJIFILM Holdings Corporation (Japan), Eigen Health (US), Focal Healthcare (Canada), Esaote SPA (Italy), MTT GmbH (Germany), MedCom (Germany), UC-CARE Medical Systems (US), Biobot Surgical (Singapore), Canon Inc. (Japan), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Fusion Biopsy Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
